An observational study in Cerebral (CVAs), Ischemic Cerebrovascular Accident and Stroke, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2023-05-26.
Sponsored by University Hospital, Brest · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Ischemic Stroke with a site in France — 56 open to participants now, 61 under way, 10 of them phase 3. Ischemic Stroke · France.
Among the 164 studies in Ischemic Stroke with a site in France, this one is the 3rd largest by planned enrollment of the 55 observational ones that give a count, is one of 4 that started in 2008, is one of 55 observational ones, reaches primary completion later than 0 of the 60 other live ones, and was the 46th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →56 of the 164 studies in Ischemic Stroke with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Takeda · Sites in France, United States, Belgium and 7 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–80
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Neuravi Limited · Sites in France, Belgium, Germany and 1 more country
Ages 18–90
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 15 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 25 · Phase 3 25 · Phase 4 4
First in 1990; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15,000 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 186 across the 109 interventional studies, 250 across the 55 observational. Of the 91 that completed or were terminated, 14 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 164 have an industry lead sponsor. The 10 most frequent:
University Hospital, Brest is the lead sponsor of 602 studies on the registry; 137 are open to participants now.
University Hospital, Brest has 3 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
15 of the studies in Ischemic Stroke with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT06059144Phase 3University Hospital, BordeauxInduced Hypertension in Acute PRogrESsive Perforating Artery Stroke Using Peripheral Dilute noREpinephrine | 2027-08-28 |
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT06071091Assistance Publique - Hôpitaux de ParisPermanent Intracranial Stenting for Acute Ischemic Stroke Related to a Refractory Large Vessel Occlusion | 2027-02-01 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
Add all 15 to your calendar (.ics) → With an account.
Among the 164 studies in Ischemic Stroke with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The registry is the main objective exhaustive list of cases validated stroke brain on a geographical area defined to calculate an incidence.
The main objective of Brest Stroke Registry is to regroup all confirmed cases of stroke over a defined geographical zone in order to calculate an incidence.
There are three prospective medium-term goals:
In clinical terms, the registry offers an opportunity to do an inventory of all current practices (diagnosis, therapies and the subsidiaries) and propose in this manner the best management of stroke. This strategy is in line with the pilot programs deployed by the French High Health Authority (HAS) for improvement of quality and safety of the health care. The bleeding risk associated with anticoagulants and anti-platelet agents in people of Brest as well as that of Dijon and Lille (in collaboration with their respective registry) will be analyzed.
This study has gained a particular characteristic since 2012 with emerging new oral anticoagulants (OAC) which have shown less associated bleeding risks compared with vitamin K antagonists (randomized controlled trials).
•In terms of clinical research :
Diagnostic validated for one of the following pathologies:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Type of stroke (ischemic or haemorrhagic)
The type of stroke ischemic or haemorrhagic will be collected from physician diagnostic
Time frame: Inclusion
Patient outcome
Patient outcome (mortality) wanted by mail from towns of birth
Time frame: Every year after the inclusion during 10 years
Plan to share: Yes
No publications or documents are linked to this record.
Ran from Jan 2008 to primary completion in Aug 2016, 103 months.
Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's 103 months is above that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.